On The Mechanisms Of Development Of Widespread Pain | 45723
Journal of Pain & Relief
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Pain usually starts in a localized region and in the majority of chronic pain syndromes over time it can spread to encompass
multiple body regions. The current hypothesis is that this wide spread pain is related to the development of central sensitization.
In a series of reproduced studies the author has found that a different mechanism may be involved. An increased excretion of
amino acids (a diuresis event) correlated with the exacerbation of pain (VAS scores) but the excretion declined with duration of the
pain syndrome suggesting a whole body amino acid depletion event. These events were associated with changes in serum sodium,
osmolality and the presence of widespread pain. The fall in serum amino acids correlated with a fall in urea in both serum and urine
which appeared to be associated with the change in the renal function. Assessment of eGFR revealed that few patients had evidence
of kidney disease. These changes seem to mimic, at a lower level, those seen with Diabetes Insipidus or a Syndrome of Inapproriate
Antidiuretic Hormone excretion (SIADH). No patients could be classified as SIADH as the osmolality and sodium levels were not
outside the normal two standard deviation limits. It appears that an inflammatory mediated change in protein synthesis occur via the
EIF2 and mTORC1 gene pathways. A hypothesis based upon epigenetic influences on EIF2 associate protein synthesis inhibition will
be presented including the potential roles of posture, malabsorption, exercise, viral dsRNA and bacterial toxins in the development
of pain syndromes.
Neil R McGregor completed his PhD at University of Sydney, Australia and is involved in university based studies at the Bio21 Institute at the University of Melbourne. He is a Consultant at Bioscreen Pty Ltd which is involved in the research and testing of the human gut microbiome. He has published more than 60 papers in peer reviewed journals and many as a coauthor with research groups in the US and Europe. He was a former co-editor of the Journal of Chronic Fatigue Syndrome, Philadelphia USA.